Enovix Corporation — Q1 2024 Form 10-Q
Reporting period: Quarter ended March 31, 2024. Financial statements are unaudited; comparisons are with the quarter ended April 2, 2023. Enovix develops and manufactures lithium-ion batteries. Results include Routejade, acquired in October 2023, so year-over-year comparisons are not fully like-for-like.
Financial performance and liquidity
| Metric | Q1 2024 | Prior comparable quarter |
|---|---|---|
| Revenue | $5.3 million | $21,000 |
| Cost of revenue | $7.1 million | $12.2 million |
| Gross loss | $1.8 million | $12.2 million |
| Operating expenses | $68.3 million | $51.0 million |
| Loss from operations | $70.1 million | $63.3 million |
| Net loss attributable to Enovix | $46.4 million | $73.6 million |
| Basic and diluted loss per share | $0.28 | $0.47 |
| Cash used in operating activities | $35.0 million | $25.6 million |
| Property and equipment purchases | $15.1 million | $3.0 million |
Gross margin remained negative. Revenue increased mainly because of Routejade and product shipments, including $1.9 million to a South Korean military contractor. Routejade contributed $5.3 million of Q1 revenue; pro forma revenue including Routejade was approximately $5.3 million in Q1 2024 versus $5.0 million in Q1 2023.
As of March 31, 2024, cash and cash equivalents were $222.2 million, short-term investments $40.2 million, and working capital $221.1 million. Management reported $264.3 million of cash, cash equivalents, restricted cash and short-term investments. The company had an accumulated deficit of $645.2 million and stated it expects continued operating losses and negative operating cash flows.
Debt included $172.5 million principal of 3.0% convertible senior notes due May 2028, $8.5 million of short-term debt, and $168.3 million of long-term debt, net. Q1 interest expense was $1.7 million. The company also reported $57.7 million in open purchase orders and other ordinary-course contractual commitments.
Changes and unusual items
- Revenue rose from an immaterial prior-year level, reflecting Routejade and product shipments; the acquisition limits comparability.
- Operating loss increased by $6.9 million. R&D rose 105% to $48.8 million, including $18.3 million of accelerated Fab1 depreciation and $5.9 million of overhead reclassified from cost of revenue after Fab1 shifted to product development.
- SG&A decreased 28% to $19.5 million, primarily because the prior-year quarter included executive departure-related costs. Q1 2024 net loss was lower than the prior year partly due to a $21.1 million non-cash warrant fair-value gain; this gain reduced the reported warrant liability to $21.8 million.
- Stock-based compensation was $12.8 million, compared with $29.2 million in the prior-year quarter, which included substantial award-modification expense.
- Cash and cash equivalents declined from $233.1 million at year-end 2023; short-term investments declined from $73.7 million. The quarter included $51.3 million of investment maturities, $17.1 million of investment purchases, $5.8 million of net ATM equity proceeds, and $1.8 million of loan proceeds.
Business outlook, risks and contingencies
Management said available cash is expected to meet funding requirements for the next 12 months, based on anticipated spending and timing. It expects spending on operations and capital equipment to increase as it ramps manufacturing, and said longer-term needs may require additional financing. No specific revenue, earnings or production-volume guidance is provided in the filing.
- Enovix reported approximately 250,000 square feet of Fab2 space built out in Malaysia and shipments of Gen2 equipment that had cleared Factory Acceptance Testing. Management planned to begin sampling EX-1M high-cycle-life smartphone batteries in Q2 2024. A development agreement with a leading automaker and a silicon-material collaboration with Group14 were also announced.
- After quarter-end, Enovix announced plans to cease Fab1 manufacturing by July 2024, transition manufacturing to Malaysia, and reduce its U.S. workforce by approximately 200 employees. It estimated $33 million to $43 million of pre-tax restructuring charges, mostly non-cash, and cautioned that additional charges could be significant.
- Key execution risks include Gen2 installation, qualification, yield, throughput, equipment reliability, supplier delays, customer qualification timelines, and dependence on the Malaysian manufacturing arrangement. The filing notes that one supplier entered receivership in the first half of 2024, potentially delaying equipment.
- Routejade creates customer concentration exposure: the filing states one South Korean military subcontractor represented approximately 75% of 2023 revenue. Q1 2024 sales also included a $1.9 million shipment to a South Korean military contractor.
- The company disclosed ongoing wage-and-hour class actions and an amended securities class action complaint. The securities case’s initial complaint was dismissed with leave to amend; defendants moved to dismiss the amended complaint in May 2024. Management said it did not expect the disclosed matters to materially affect financial position, but outcomes remain uncertain.
- Management concluded disclosure controls were effective at a reasonable assurance level. Routejade’s acquired operations were excluded from the internal-control assessment for the first year after acquisition.
Important facts for investors to verify
- Whether Fab2 Gen2 lines complete site acceptance, customer qualification, and production ramp on schedule, with adequate yield and cost performance.
- Whether EX-1M sampling and customer qualification progress as planned, and whether shipments translate into recurring, diversified revenue.
- How much of the reported $264.3 million liquidity is available for operations, including the status and terms of the $70.0 million OCBC deposit and any restrictions if YBS draws its term loan.
- Actual timing, cash impact, and total amount of Fab1 restructuring costs, and whether the planned cost reductions affect product development or manufacturing execution.
- Customer concentration, the military contractor’s future orders, and the progress of new customer and market qualification.
- Future cash burn, capital expenditure needs, and whether additional capital or equity issuance will be required despite management’s stated 12-month liquidity expectation.
- Potential dilution or cash obligations from the convertible notes, outstanding warrants, and future financing; and developments in the disclosed litigation.